Coronary drug project

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
Coronary drug project On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Coronary drug project All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Coronary drug project
CDC on Coronary drug project
Coronary drug project in the news
Blogs on Coronary drug project
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for Coronary drug project

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Objective

To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Timeline
Start Date
End Date
Status

The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00000482.

Study Description

Study Description
Study Type	Interventional
Study Phase	Phase 3
Study Design
Allocation	Randomized
Masking	Double-Blind
Study Details
Primary Purpose	Prevention
Condition	Cardiovascular diseases; coronary disease; heart diseases; myocardial infarction; myocardial ischemia
Intervention	Drug: estrogen Drug: clofibrate clofibrate Drug: dextrothyroxine sodium Drug: niacin
Study Arms
Population Size

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00000482.

Publications

Conclusion

Pending